The FDA has approved a new product that is also an anti-wrinkle drug. Originally the name of Reloxin was going to be the name, but it appears now the drug may enter the market under the name of Dysport. Detailing side effects lead to a short delay from the manufacturer. Dysport looks to be
cheaper, so this may really push Allegan into a much more competitive mode. With the current economy, elective drug treatments have slowed down as well.
Medicis Pharma also has several other drugs on the market and the listing can be viewed here. BD
From the Website: “Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and podiatric conditions and aesthetics medicine. The Company is dedicated to helping patients attain a healthy and youthful appearance and self-image. Medicis has leading branded prescription products in a number of therapeutic categories, including acne, fungal infections, psoriasis, rosacea, seborrheic dermatitis, and skin and skin-structure infections. Additionally, the company markets the leading dermal filler in the U.S., Restylane.”
The Food and Drug Administration has approved a rival to Botox, the blockbuster wrinkle-reducing drug from Irvine-based Allergan Inc.
Medicis Pharmaceutical Corp. of Scottsdale and its partner, France’s Ipsen SA, said Thursday that regulators approved their Dysport drug as an anti-wrinkle treatment and for treating spasms of the neck muscles.
The FDA originally was set to decide on the marketing application for Dysport in mid-April. But that was delayed as Medicis and Ipsen still were in talks with regulators about labeling and detailing of side effects, which led to worries about a potential approval delay.
Medicis said it expects to launch the cosmetic form of the drug, which will use the Dysport name instead of the previously proposed Reloxin, within the next 30 to 60 days.
Orange County Business Journal Online
Related Reading:
0 comments :
Post a Comment